Skip to content
Back to Blog
Bio
2026-03-247 min read69

2026 Bio-Pharmaceutical Export Manufacturing Registration — GMP Compliance & Facility Standards Preparation Guide

A comprehensive guide to the 2026 CDMO Special Act's export manufacturing registration system, MFDS GMP compliance certification requirements, and practical preparation strategies for SME biotech companies.

KITIM Consulting Team

What Is the Export Manufacturing Registration System — Key Changes Under the CDMO Special Act

The Global Bio-Pharmaceutical CDMO Special Act, set to take effect in the second half of 2026, represents a watershed moment for Korea's biomanufacturing sector. Under the existing Pharmaceutical Affairs Act, export-only manufacturing facilities had to follow the same licensing procedures as domestic-market operations. The new Export Manufacturing Registration System creates a dedicated regulatory pathway for companies manufacturing biopharmaceuticals exclusively for export.

Here are the key differences:

  • Current system: Manufacturing license (same standards for domestic and export) → Product approval → GMP inspection (sequential)
  • New registration system: Export manufacturing registration (streamlined) → MFDS GMP compliance certification → Verification of overseas buyer requirements
  • This reform targets not only major CDMOs like Samsung Biologics and Celltrion but also small and mid-sized biotech companies with annual revenues under KRW 50 billion, aiming to lower their barriers to global market entry. The government has set a goal of expanding domestic CDMO revenue to KRW 30 trillion by 2027, making now the ideal time to begin preparations.

    MFDS GMP Compliance Certification and API Certification Framework

    The central gateway to export manufacturing registration is MFDS GMP compliance certification. In preparation for the Special Act, the Ministry of Food and Drug Safety (MFDS) is developing GMP certification standards tailored specifically to CDMO manufacturing sites.

    Key GMP Compliance Certification Requirements

  • Facility standards: Cleanroom classifications (ISO 5–8), HVAC systems, and cross-contamination prevention design based on PIC/S GMP
  • Quality management systems: QA/QC organizational independence, deviation and change management procedures, and validation documentation
  • Data integrity: ALCOA+ compliance, electronic records management systems (LIMS/MES)
  • Certification validity: 3 years (with renewal audits), subject to immediate suspension for critical deficiencies
  • Active Pharmaceutical Ingredient (API) Certification

    The API certification system is also being formalized. APIs that receive prior MFDS certification will benefit from streamlined import clearance documentation, reducing average customs processing from 15–20 days to under 5 days.

    Leveraging Regulatory Support Services

    MFDS is offering pre-consultation and technical advisory services ahead of the Special Act's implementation:

  • Pre-consultation: Pre-submission review of facilities and documentation for GMP certification (free, up to twice per year)
  • Technical advisory: Regulatory interpretation and guideline support for biopharmaceutical manufacturing processes
  • Regulatory sandbox: Temporary approval pathways for innovative manufacturing technologies such as continuous processing
  • Practical Preparation Checklist for SME Biotech Companies

    1. Facility and Equipment Investment Priorities

    SMEs preparing for GMP certification with limited budgets must clearly prioritize their investments:

  • HVAC and cleanroom systems — The most frequently cited deficiency in GMP inspections (approximately 30% of all findings)
  • Quality control equipment (HPLC, mass spectrometry, etc.) — Building in-house testing capabilities
  • MES/LIMS systems — Meeting data integrity requirements and transitioning to electronic batch records
  • 2. Workforce Development and Quality Culture

  • K-NIBRT (Korea National Institute for Bioprocessing Research and Training): Hands-on biopharmaceutical manufacturing process training and GMP specialist certification programs (approximately 1,000 trainees annually)
  • Internal QA/QC staffing: A minimum of 3–5 dedicated quality management personnel recommended
  • Mock audits: Pre-inspection assessments through external specialists to identify gaps before formal MFDS audits
  • 3. Government Support Programs

  • Bio-dedicated funds: KRW 500 billion CDMO-specific fund jointly operated by Korea Development Bank and Growth Finance
  • R&D support: Cross-ministerial bio-industry R&D programs (approximately KRW 2 trillion annually), including CDMO process innovation projects
  • Facility investment grants: Up to 50% matching support for facility costs for companies located in bio-specialized complexes (Osong, Songdo, Hwaseong)
  • Tax incentives: Up to 25% tax credit for bio facility investments (SME basis)
  • KITIM Consulting Implications

    The implementation of the export manufacturing registration system presents both opportunities and challenges for Korean biotech companies. From GMP compliance certification preparation to government subsidy applications, a systematic strategy is the key to success.

    KITIM (Korea Institute of Technology Innovation Management) provides GMP certification consulting and government funding program integration strategies for the bio-pharmaceutical sector. We offer end-to-end support covering export manufacturing registration roadmap development, R&D project planning, and facility investment grant applications. Contact KITIM today for a customized consulting engagement.

    Export Manufacturing RegistrationBio GMP ComplianceCDMO Facility StandardsMFDS Regulatory ReformBio SME

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.